Guardant Health, Inc. (GH)
收市後：
| 前收市價 | 31.19 |
| 開市 | 30.59 |
| 買盤 | 28.97 x 1300 |
| 賣出價 | 29.05 x 1300 |
| 今日波幅 | 28.98 - 30.79 |
| 52 週波幅 | 15.81 - 41.06 |
| 成交量 | |
| 平均成交量 | 2,354,338 |
| 市值 | 3.551B |
| Beta 值 (5 年，每月) | 1.15 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.92 |
| 業績公佈日 | 2024年8月01日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 36.17 |
ZacksGuardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
Investor's Business DailyGuardant Health Jumps — As Exact Sciences Slumps — On A Key FDA Move For Blood Tests
Guardant Health stock jumped Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.
Barrons.comGuardant Health Stock Jumps. Blood Test for Cancer Moves Toward FDA Approval.
Shares of Guardant Health were rising sharply after the cancer company said a Food and Drug Administration advisory committee recommended the agency approve the company’s blood test for colorectal cancer screening. The test, Shield, is for people 45 and older who are at average risk for the disease, according to the release. “The recommendation signals the advisory committee panel’s consensus on Shield’s safety and effectiveness with its proposed intended use, and their conclusion that its benefits as a primary non-invasive screening option outweigh any potential risks,” according to the release.
